

Guillain-Barré Syndrome

**A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Crovalimab in Participants With Guillain-Barré Syndrome (GBS)**

**Trial Status**  
Withdrawn

**Trial Runs In**  
0 Countries

**Trial Identifier**  
NCT05494619 2021-002968-49  
BN43118

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of crovalimab compared with placebo as an add-on therapy to intravenous immunoglobulin (IVIg) in participants with severe GBS.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

**NCT05494619 2021-002968-49 BN43118**  
Trial Identifiers

***Eligibility Criteria:***

**Gender**  
All

**Age**  
≥18 Years

**Healthy Volunteers**  
No